Neuroscience ACCUMIN brings together world-class thought leaders from Psych Congress and the Neuroscience Education Institute to share insight that informs data generation and medical, marketing, and business strategies.

The field of neuroscience is increasingly dynamic as the demand for treatment and management of neuropsychiatric disorders grows.

With the global market for central nervous system therapeutics projected to reach $137 billion this year, it is more important than ever for neuroscience stakeholders to have an unbiased and timely analysis of the latest data releases, FDA announcements, and market activity. Neuroscience ACCUMIN provides that competitive edge in this increasingly dynamic field.

Neuroscience ACCUMIN brings together an Expert Panel of world-class thought leaders from Psych Congress and the Neuroscience Education Institute to share timely insights that can inform data generation and medical, marketing, and business strategies.

Neuroscience ACCUMIN Desk, a real-time intelligence portal, provides 24/7 access to:

• Publication Portal: A searchable index of curated data announcements and publications, including expert insight into the impact of key data readouts  
• Market Movers: A live feed of the top stories of the week in neuroscience, including news, analyst opinions, and mergers and acquisitions updates  
• Congress Highlights: Live and archived congress briefings and insights from our Expert Panel

The strength of Neuroscience ACCUMIN lies in its Expert Panel. This panel of thought leaders delivers unbiased, real-time insight into the changing neuroscience landscape and offers context and clarity around emerging data and trends.  

The ACCUMIN Impact Score is the quickest way to get expert perspectives into the importance of new data. When our Expert Panel reviews data, they provide understanding into how impactful those data are across three categories: science, molecule, and class. These three scores are then averaged to create the ACCUMIN Impact Score.  

Watch the video to learn how our Expert Panel assigns ACCUMIN Impact Scores:

The Neuroscience ACCUMIN Expert Panel provides unbiased perspectives to empower decision-makers in pharmaceuticals, finance, and other healthcare-related industries, helping them understand the implications of new developments in neuroscience and leverage these insights to set effective growth strategies for their businesses. 

Contact us today to learn more.

Psychiatrist Greg Mattingly, MD, is Chief Medical Officer at Neuroscience ACCUMIN, CEO of Midwest Research Group, and an Associate Clinical Professor at Washington University.